This article is more than 5 years old. Information may no longer be current.

Lumigan granted first-line treatment designation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Once-daily bimatoprost has been granted regulatory approval for use as a first-line treatment for elevated IOP associated with open-angle glaucoma or ocular hypertension, the product’s manufacturer said in a news release.

Allergan said the Lumigan (bimatoprost) 0.03% first-line indication is in addition to the drug’s approval for second-line use.